A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFRmutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment

Brief description of study

This study is to see if a new medicine called AK112 can help patients with advanced non-squamous non-small cell lung cancer (NSCLC) that didn't get better with their previous treatment. The study team will compare AK112 when used with two other drugs, pemetrexed and carboplatinwith, with a fake medicine (placebo) when used with the same two other drugs, pemetrexed and carboplatinwith. People in the study will be split into two groups based on their previous treatment and whether they have cancer in their brain or not. One group will get AK112 with the two other drugs, and the other group will get the fake medicine with the same two drugs. The study will check if AK112 helps people live longer and if it stops tNSCLC from getting worse. There will be a special team that watches for any problems and decides if the study should continue. Patients will be checked at different times during and after the treatment to see how they are doing and if they need more treatment. They will also look at any side effects people have while taking the medicine. This study is important to find better ways to treat this type of lung cancer.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.